1. Updates in Migraine From a 2018 American Headache Meeting

2. This program will include a discussion of off-label treatments, devices, and investigational agents not approved by the FDA for use in the United States, and the data were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Acute Treatment of Migraine

4. Use of Acute Rx Treatments Among CaMEO Study Participants

5. MAST Study of Unmet Needs in Migraine

6. RDBPC, Phase 3, Trials of Lasmiditan: SAMURAI and SPARTAN

7. Dizziness in SAMURAI and SPARTAN

8. Sumatriptan and Lasmiditan Inhibit KCl-Induced CGRP release

9. Multicenter, RDBPC, Phase 3, Single-Attack Trial of Ubrogepant

10. Ubrogepant in Adults With Migraine: Results

11. Phase 3, RDBPC, Trial of Rimegepant in Adults With Migraine: Study Design

12. Rimegepant in Adults With Migraine: Results

13. Sumatriptan vs Rimegepant vs BHV-3500

14. Prevention of Migraine

15. Prevention of Migraine: FDA Status of mAbs

16. RDBPC 12-Week Trial of Fremanezumab for Preventative Treatment of EM: Onset of Efficacy

17. Rapid Onset of Galcanezumab for the Prevention of EM: EVOLVE-1 and EVOLVE-2

18. Onset of Efficacy in Phase 3 PROMISE-2 CM Trial

19. Reversion of CM to EM With CGRP-Targeted mAbs

20. Post-hoc Analysis of RDBPC Phase 3 Trial of Erenumab in CM: Conversion to EM

21. Post-hoc Analysis of RDBPC Phase 3 Trial of Fremanezumab in CM: Reversion of EM

22. The Prevention of Migraine With CGRP-Targeted mAbs: Long-Term Results

23. Long-Term Data With Erenumab in CM

24. Treatment of EM and CM Response Over Time With Fremanezumab

25. The Efficacy of CGRP-Targeted mAbs in Previous Treatment Failure

26. Galcanezumab After Treatment Failure to OnabotulinumtoxinA in Patients With Migraine

27. EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments

28. EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments (cont)

29. EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments (cont)

30. Multicenter RDBPC Phase 3a Liberty Trial of Erenumab: Response in Patients With Preventive Treatment Failures

31. Wolff Award Lecture

32. Endotypes of Migraine Derived From CaMEO Data

33. Abbreviations

34. Abbreviations (cont)